Synaptogenix (Nasdaq: SNPX) Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength. Read the press release here: https://prn.to/4gK6VrX
Synaptogenix, Inc.
制药业
New York，NY 212 位关注者
Clinical-stage biopharmaceutical company working to develop novel therapies for neurodegenerative diseases
关于我们
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.
- 网站
-
https://www.synaptogen.com/
Synaptogenix, Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- New York，NY
- 类型
- 上市公司
地点
-
主要
获取路线
US，NY，New York，10036
Synaptogenix, Inc.员工
动态
-
Synaptogenix (Nasdaq: SNPX) Announces $5.0 Million Financing From Existing Investors. Read the press release here: https://prn.to/3TqwULQ
-
ICYMI: New collab to probe potential of fatty acid analogs in #Alzheimer's. Our collaboration with LSU Health Sciences Center New Orleans will focus on pre-clinical testing of our polyunsaturated fatty acid analogs for treating spinal cord injuries. Read more via The Pharma Letter: https://bit.ly/3LTul0r #PreclinicalResearch #Biopharmaceutical #Neuroscience
-
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in #SpinalCordInjury. Read the press release here: https://prn.to/46iaYrp LSU Health Sciences Center New Orleans #PreclinicalResearch #Biopharmaceutical #Neuroscience
-
Preclinical data suggest that Bryostatin-1 has promising potential as a therapeutic agent for #MS. Read more about the collaborative study that will evaluate the drug's potential to improve synaptic health and #cognitive function in MS patients: https://bit.ly/3L0l5Y3 #ClinicalResearch #Neuroscience #Biopharma
-
Yesterday, we announced that the FDA has authorized an IND application for Bryostatin-1 as a potential treatment for #multiplesclerosis. Read more in the press release here: https://bit.ly/3L0l5Y3 #ClinicalResearch #Neurology
-
Synaptogenix (Nasdaq: SNPX) Announces FDA Authorization of IND Application for #ClinicalTrial for Bryostatin-1 in #MultipleSclerosis. Read the press release here: https://bit.ly/3L0l5Y3 #Neuroscience #Biopharma
-
Synaptogenix (Nasdaq: SNPX) Applauds DEA Proposal to Reclassify #Cannabis and Shares Expected Benefits to Cannasoul for #Cannabinoid-Based #DrugDiscovery. Read the press release here: https://prn.to/3WqMVDP #Biopharma
-
Synaptogenix increases #psilocybin stake with PsygaBio. Read more about our latest news via Green Market Report: https://bit.ly/4aslWvV #Biopharma #Psychedelics
-
Synaptogenix (Nasdaq: SNPX) Increases Stake in Innovative #Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics. Read the press release here: https://prn.to/4aM6ryr #BusinessUpdate #Biotech #Pharma